Back to all molecules
Limited / uncertainNot FDA-approved

Selank

Synthetic tuftsin-related heptapeptide

Also indexed as: Tuftsin analog

What this evidence does not tell us

The supplied conference-style citation could not be independently verified. Independent replication and broadly applicable clinical outcome evidence are limited.

Terms on this page

Unfamiliar word? Open this panel for simple explanations, right here.

6 glossary terms used in this profile

Select a word to see its meaning. You can keep more than one definition open.

Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.

Overview

Selank is a synthetic heptapeptide related to tuftsin. It is discussed in anxiety-related and neuropeptide research, but this edition could not independently match the supplied clinical citation.

Mechanism of action

Tuftsin-related / neuropeptide signaling

Research proposes effects on neuropeptide and inhibitory signaling, including GABA-related pathways. A definitive mechanism for broadly reproducible human clinical benefit is not established.

A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.

Decode the terminology in our glossary

Scientific evidence

How strong is the evidence?

Not enough reliable evidence

  1. Limited evidenceCurrent category
  2. Early research
  3. Human research
  4. Human outcomes

There is too little dependable or verified research here to draw a useful conclusion about benefit in people.

For this research: The supplied conference-style citation could not be independently verified. Independent replication and broadly applicable clinical outcome evidence are limited.

An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.

Cell studies

Mechanistic laboratory evidence is not separately assessed in this selected-source summary; see references and their study types.

Animal experiments

Animal evidence is not separately assessed here. Findings in animals must not be interpreted as demonstrated human benefit.

Human observational studies

Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.

Human clinical trials

Reliable, independently replicated human outcome evidence is not established by the selected sources in this edition.

Regulatory evidence

No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.

Potential research applications

Anxiety-related signaling and neurobehavioral hypotheses.

These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.

Explore research by health goal

Safety considerations

FDA identifies insufficient safety information and possible immunogenicity and impurities. Interactions with psychiatric and sedative medicines are poorly characterized.

This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.

Read FDA’s compounding safety information

Regulatory status · United States

Not FDA-approved

No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.

Regulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.

Selected literature & source transparency

Unverified reference· 2012Citation not verified

Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic selank

European Psychiatry

Bibliographic match not independently verified. Not used as support for clinical benefit.

Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.

Continue your own source search

These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.

Three questions worth bringing to your clinician

  1. Which human outcomes—not just biomarkers—support this claim?
  2. What established options address my actual health concern?
  3. What do my medical history and current medicines change about the risks?

Beyond the library

Turn better questions into a thoughtful conversation.

Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.

Request an Optimization Consultation

Continue to our existing activation & intake page.

Education, not a prescription. Research summaries are not medical advice, dosing instructions, or an offer to sell. Mechanistic findings do not establish clinical effectiveness. US regulatory status is product- and indication-specific and may change. Discuss health decisions with a licensed clinician.